Publicaciones en colaboración con investigadores/as de Università degli Studi di Siena (1)

2023

  1. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2